Myeloproliferative Neoplasms
Research activity includes essential thrombocythaemia, with a focus on treatment options for patients who are intolerant of, refractory to, or unsuitable for other cytoreductive therapies.
- Essential thrombocythaemia
- ELN response criteria
- Cytoreductive treatment
The clinical interest in this area centres on disease control in a chronic myeloproliferative neoplasm setting.
Pulmonary Arterial Hypertension
Trials address pulmonary arterial hypertension in Group 1 disease, with attention to therapeutic strategies that combine oral and parenteral treatment approaches.
- Pulmonary arterial hypertension
- Group I PAH
- Combination therapy
This area reflects interest in improving vascular disease management in patients with pulmonary vascular disease.
Paediatric Pulmonary Vascular Disease
Research also extends to paediatric pulmonary arterial hypertension, with evaluation of treatment tolerability in children and adolescents affected by Group 1 pulmonary hypertension.
- Paediatric PAH
- Pulmonary hypertension
- Tolerability in children
The sponsor’s portfolio includes the paediatric cardiopulmonary domain, where long-term management and formulation suitability are important therapeutic concerns.
Acute Myeloid Leukaemia and Myelodysplastic Syndromes
Clinical research covers relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndrome, with interest in oral anti-cancer therapy for heavily pretreated haematologic malignancies.
- Relapsed/refractory AML
- High-risk MDS
- Haematologic malignancies
This therapeutic focus lies within oncology and haematology, particularly in difficult-to-treat marrow disorders.
